euro adhoc: Intercell AG / other / Intercell announces initiation of further Phase II clinical trial of V710 an investigational vaccine to prevent S. aureus infection

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

28.08.2008

Vienna (Austria), August 28, 2008 - Intercell AG (VSE: ICLL) today
announced that its collaborator Merck & Co., Inc. has initiated a
Phase II clinical trial of V710, an investigational vaccine for the
prevention of Staphylococcus aureus (S. aureus) infections. This
randomized double blind, placebo controlled study aims to evaluate
the safety and immunogenicity of the vaccine candidate in patients
with end-stage kidney disease on hemodialysis. This trial start
follows the initiation of a separate Phase II trial in December 2007.

Gerd Zettlmeissl, CEO of Intercell, commented "We are very pleased
that our strategic partner Merck has chosen to initiate a further
Phase II clinical trial. We look forward to continued progress of the
program building on clinical data obtained so far."

The S. aureus vaccine candidate is based on a conserved protein
antigen discovered by Intercell and licensed to Merck & Co., Inc. in
2004 on an exclusive world wide basis. Merck is responsible for
clinical development, manufacturing and marketing. Intercell is
eligible to receive milestone payments and royalties on future net
sales. In Phase I clinical trials the S. aureus candidate vaccine was
shown to be immunogenic and generally well tolerated.

Hospital-acquired Infections

Hospital-acquired infections caused by bacteria are one of the major
causes of death and serious illness. Intercell has embarked on a
large scale, comprehensive and multi-target antigen identification
program to contribute to vaccine efforts in this field. Besides
Merck's S. aureus vaccine, based on an antigen identified by
Intercell, Intercell is developing a vaccine against
hospital-acquired infections caused by Pseudomonas aeruginosa (Phase
II/III trial is expected to be initiated in 2008) and a Pneumococcus
vaccine (Phase I trials planned for end 2008). Furthermore Intercell
has ongoing pre-clinical programs for Enterococcus and Klebsiella
vaccine discovery.

About S. aureus

S. aureus is the most frequent cause of hospital-acquired infections.
In addition to bloodstream infections with a mortality rate of up to
35%, infections of bone, heart and other inner organs are leading to
serious health complications, death and economic burden. Today,
approximately 50% of S. aureus strains isolated in hospitals
worldwide are resistant to multiple antibiotics, rendering
staphylococcal disease management increasingly difficult and
challenging. Hospital-acquired infections are one of the major causes
of death and serious illness worldwide, resulting in an annual burden
of more than USD 20 billion in the developed world. In the United
States alone, about two million patients become infected annually
while receiving health care in hospitals.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Communications

Tel. +43 1 20620-303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market